/
Oncology
Esophageal Cancer
214
Pipeline Programs↗
300
Active Trials↗
94
Companies Involved↗
Esophageal Cancer is a highly competitive landscape with 214 programs across 94 companies. The most active players are Sunshine Lake Pharma Co., Ltd., Beijing Konruns Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 46 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical37
Phase 123
Phase 2108
Phase 346
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
150 of 194 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 194 classified programs, each share of the total. Modality classified for 94% of 214 pipeline programs.
Analysis
Trial Status
826
clinical trials
Completed251 · 30%
Unknown status194 · 23%
Recruiting165 · 20%
Not yet recruiting74 · 9%
Terminated58 · 7%
Active, not recruiting54 · 7%
Other30 · 4%
Clinical Trials
Trial Activity
826 trials
Page 1 of 56
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)